I've got to do a bit of work to do on this but $4 may be realistic, with $6 plus an eventuality. I think it's more a question of time than result. FDA and government going along given the news.
Breaking the $2 barrier, perhaps we might see $4 sooner than I originally thought?
Today PR...
AVANT CEO to Present at the Needham & Company Biotechnology Conference
Thursday May 29, 8:00 am ET
NEEDHAM, Mass.--(BUSINESS WIRE)--May 29, 2003--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - News) today announced that Dr. Una S. Ryan, President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will present at the Needham & Company Second Annual Biotechnology Conference at the New York Palace Hotel in New York City on Friday, June 6th at 10:30am, ET.
A live webcast of the 30-minute presentation, together with a read-only copy of the presentation slides in Adobe Acrobat (.pdf) format, will be available online via the Investor Information area of AVANT's website at avantimmune.com and at twst.com. An archive of the webcast will be available via AVANT's website for 60 days following the event.
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a broad portfolio of vaccines addressing a wide range of applications including bacterial and viral diseases, chronic human disease, biodefense and food safety. These include single-dose, oral vaccines that protect against important disease-causing agents and a novel, proprietary vaccine candidate for cholesterol management. AVANT's goal is to demonstrate proof-of-concept for its products before leveraging their value through partnerships. Current collaborations encompass the development of an oral human rotavirus vaccine, vaccines to combat threats of biological warfare, and vaccines addressed to human food safety and animal health.
Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: avantimmune.com.
--------------------------------------------------------------------------------
Contact:
AVANT Immunotherapeutics, Inc.
Una S. Ryan, Ph.D., 781/433-0771
or
AVANT Immunotherapeutics, Inc.
Avery W. Catlin, 781/433-0771
info@avantimmune.com
or
For Media:
Kureczka/Martin Associates
Joan Kureczka, 415/821-2413
jkureczka@aol.com
--------------------------------------------------------------------------------
Source: AVANT Immunotherapeutics, Inc. |
